Novelion Therapeutics Inc (Nasdaq:NVLN) Ends Day Up 32.65%

0
15
NVLN
NVLN

Novelion Therapeutics Inc (Nasdaq:NVLN)

December 5th, 2018
Amidst falling markets Novelion Therapeutics Inc closed Tuesday up 32.65%, a $0.32 increase to close on $1.30. Two technical ‘scores’ for companies to be aware of are the Altman Z1 and the Piotroski2 scores. NVLN scored quite low for both, which could be indicators of trouble down the road (the Altman Z-Score is -3.69, and the Piotroski Score is 2). In addition to finishing higher, trading volumes were solid at 524% of normal which can indicate investors see opportunities.

NVLN outperformed the rest of the Healthcare sector which went down 2.30% today.

Market Sectors

The market sectors were mixed Wednesday with a majority of the sectors trending down. Utilities saw the biggest increase of the day (0.15%), while Financials saw the biggest drop (4.40%). Healthcare has seen the biggest year-to-date gain at 13%. The biggest loss this year has been the Communication Services sector dropping 13%.

Utilities saw the biggest turnaround from its 5-day performance of 2.31%, as it went up 0.15%. Industrials and Consumer Discretionary saw turn arounds from their five day positive performance, Industrials with a drop of 4.35%.

Sector Breakdown

  • Utilities went up with a 0.15% change.
  • Real Estate went down with a -1.26% change.
  • Consumer Staples went down with a -1.63% change.
  • Healthcare went down with a -2.30% change.
  • Energy went down with a -2.93% change.
  • Materials went down with a -3.08% change.
  • Communication Services went down with a -3.14% change.
  • Information Technology went down with a -3.86% change.
  • Consumer Discretionary went down with a -3.91% change.
  • Industrials went down with a -4.35% change.
  • Financials went down with a -4.40% change.

Novelion Therapeutics Inc Info

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company’s commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.

All amounts in USD unless otherwise indicated

(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that Novelion Therapeutics Inc’s score is -3.69) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.

(2) The Piotrosky score is used to determine the best value stocks with nine being the best and zero being the worst. It is based on specific aspects of the company’s financial statements, such as positive net income, operating cash flow and asset turnover ratio. A score 0 0 is the worst (Novelion Therapeutics Inc’s score is 2), and 9 is the best.

NVLN daily update
NVLN daily update


Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

This site uses Akismet to reduce spam. Learn how your comment data is processed.